Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Jun Min Zhou"'
Autor:
Robert Dalton, Alexandra Calescibetta, Jun Min Zhou, Michelle Maurin, Grace Ward, Thu Le Trinh, Nhan Tu, Danielle Gilvary, Xianghong Chen, Pingyan Cheng, Elena Kostenko, Sheng Wei, Kenneth L. Wright, Erika A. Eksioglu
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 3, p 1241 (2021)
Dendritic cells (DCs) are professional antigen presenting cells with a great capacity for cross-presentation of exogenous antigens from which robust anti-tumor immune responses ensue. However, this function is not always available and requires DCs to
Externí odkaz:
https://doaj.org/article/55956b22ad4443f2bf311ec3923596e6
Autor:
Hailey W. Bulls, Pi‐Hua Chang, Naomi C. Brownstein, Jun‐Min Zhou, Aasha I. Hoogland, Brian D. Gonzalez, Peter Johnstone, Heather S. L. Jim
Publikováno v:
Cancer Reports, Vol 5, Iss 3, Pp n/a-n/a (2022)
Abstract Background Racial and ethnic disparities are well‐documented in cancer outcomes such as disease progression and survival, but less is known regarding potential disparities in symptom burden. Aims The goal of this retrospective study was to
Externí odkaz:
https://doaj.org/article/b960d00d700d49caab749cf3569b75ea
Autor:
Anne Kuritzky, Chantal Reyna, Kandace P. McGuire, Weihong Sun, Sara M. DeSnyder, Staci Aubry, Apoorve Nayyar, Paula Strassle, Kelly K. Hunt, Jun-Min Zhou, Marie Catherine Lee
Publikováno v:
Breast, Vol 51, Iss , Pp 29-33 (2020)
Introduction: A 2014 consensus statement from the Society of Surgical Oncology and American Society for Radiation Oncology supported “no ink on tumor” as an adequate margin for breast conserving therapy (BCT). This study evaluates this statement
Externí odkaz:
https://doaj.org/article/23716931be034bf585068038cc104fc1
Autor:
Jun-min Zhou, Shui-qing Hu, Hang Jiang, Yi-lin Chen, Ji-hong Feng, Zheng-quan Chen, Kun-ming Wen
Publikováno v:
Molecular Therapy: Oncolytics, Vol 15, Iss , Pp 7-20 (2019)
Cancer stem cells (CSCs) are the main cause of tumor generation, recurrence, metastasis, and therapy failure in various malignancies including colorectal cancer (CRC). Accumulating evidence suggests that tumor cells can acquire CSC characteristics th
Externí odkaz:
https://doaj.org/article/11f053795ad144e989d13b39e5790f02
Autor:
Jonathan Chatzkel, Jesse Mocha, Johnna Smith, Jun-Min Zhou, Youngchul Kim, Ghassan El-Haddad, Jingsong Zhang
Publikováno v:
Future Science OA, Vol 6, Iss 1 (2020)
Aim: Radium-223 improves overall survival in patients with metastatic castration-resistant prostate cancer to the bone. Radium-223 causes double-strand DNA breaks and produces γH2AX, a potential biomarker for response. We examined the feasibility of
Externí odkaz:
https://doaj.org/article/e5b46b5f96ae4ef3849286cf0d89d1f3
Autor:
James Yu, Estrella Carballido, Richard D. Kim, Maria Elena Martinez, Iman Imanirad, Michael J. Schell, Jun-Min Zhou, Elaine Tan, Dae-Won Kim, Rutika Mehta, Jonathan R. Strosberg
Publikováno v:
Br J Cancer
BACKGROUND: MMR proficient (pMMR) colorectal cancer (CRC) is usually unresponsive to immunotherapy. Recent data suggest that ibrutinib may enhance the anti-tumour activity of anti-PD-1 immunotherapy. In this study, we evaluated the safety and efficac
Autor:
Apoorve Nayyar, Kelly K. Hunt, Anne Kuritzky, Jun Min Zhou, Sara M. DeSnyder, Kandace P. McGuire, Paula D. Strassle, Staci Aubry, Marie Catherine Lee, Weihong Sun, Chantal Reyna
Publikováno v:
The Breast : official journal of the European Society of Mastology
Breast, Vol 51, Iss, Pp 29-33 (2020)
Breast, Vol 51, Iss, Pp 29-33 (2020)
Introduction A 2014 consensus statement from the Society of Surgical Oncology and American Society for Radiation Oncology supported “no ink on tumor” as an adequate margin for breast conserving therapy (BCT). This study evaluates this statement i
Autor:
Michael J. Schell, Benjamin D. Powers, Takuya Ogami, Jun-Min Zhou, Danielle K. DePeralta, Pamela J. Hodul, Mokenge P. Malafa, Jason B. Fleming
Publikováno v:
HPB (Oxford)
BACKGROUND: Adjuvant chemotherapy is the standard of care for resected pancreatic ductal adenocarcinoma (PDAC). It is estimated that only 40–80% eligible patients initiate intended adjuvant chemotherapy. Completion rates are largely unknown. METHOD
Autor:
Hang Jiang, Yi-lin Chen, Shui-qing Hu, Zheng-quan Chen, Kun-ming Wen, Jun‑Min Zhou, Ji-hong Feng
Publikováno v:
Molecular Therapy: Oncolytics, Vol 15, Iss, Pp 7-20 (2019)
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics
Cancer stem cells (CSCs) are the main cause of tumor generation, recurrence, metastasis, and therapy failure in various malignancies including colorectal cancer (CRC). Accumulating evidence suggests that tumor cells can acquire CSC characteristics th
Autor:
Michael J. Schell, Jun-Min Zhou, Jonathan R. Strosberg, Mauro Cives, Heloisa P. Soares, Taymeyah Al-Toubah
Publikováno v:
Neuroendocrinology
Background: Ibrutinib is an orally administered inhibitor of Bruton’s tyrosine kinase (Btk). Preclinical data suggest that mast cells are recruited within neuroendocrine neoplasms (NENs) where they stimulate angiogenesis and tumor growth. Ibrutinib